Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Prothena
Biotech
Prothena Alzheimer's trial hit by ARIA showstopper
The phase 1 trial linked Prothena’s anti-amyloid beta antibody to a higher rate of brain swelling than rival approved drugs.
Nick Paul Taylor
Aug 28, 2025 6:48am
Prothena lays off 63% in fallout from phase 3 amyloidosis fail
Jun 20, 2025 2:23am
Prothena reburies drug after 2nd swing at rare disease misses
May 27, 2025 3:33am
Roche's Prothena-partnered Parkinson's prospect fails phase 2b
Dec 19, 2024 4:31am
UCB-Novartis Parkinson's asset fails to improve symptoms in ph. 2
Dec 16, 2024 3:19pm
Prothena promotes one exec while another leaves—Chutes & Ladders
Oct 4, 2024 8:00am